Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients

Breast Cancer Research and Treatment

Volumn 43, Issue 1, 1997, Pages 87-95

  Fehm, Tanja ^a   Maimonis, Peter ^b   Weitz, Stephen ^c   Teramoto, Yosh ^c   Katalinic, Alexander ^a   Jäger, Wolfram ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Ciba Corning Diagnostics Corp   (United States)

^c Ciba Corning Diagnostics Corp   (United States)

Author keywords

Breast cancer; c erbB 2; Chemotherapy; Oncogene; Prognosis; Survival

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GENE PRODUCT; HORMONE RECEPTOR; METHOTREXATE; MITOXANTRONE; PLASMA PROTEIN; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOSOL; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; MITOXANTRONE; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0031048153     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005700812422     Document Type: Article

References (30)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/proto-oncogene in human breast cancer and ovarian cancer. Science 244: 707-712, 1989
2. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434-438, 1991
3. Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SAW, Killander D, McGuire WL: Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337, 1990
4. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: Her-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-1128, 1989
5. Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439-443, 1991
6. Tanner B, Friedberg T, Mitze M, Beck T, Oesch F, Knapstein PG: c-erbB-2 oncogene expression in breast carcinoma: analysis by S1 nuclease protection assay and immuno-histochemistry in relation to clinical parameters. Gynecol Oncol 47: 228-233, 1992
7. Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of her-2 oncoprotein expression in breast cancer: a 30 year follow-up. J Clin Oncol 10: 1044-1048, 1992
8. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8: 103-112, 1990
9. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein overexpression with high rale of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650-655, 1991
10. Kynast B, Binder L, Marx D, Zoll B, Schmol HJ, Oellerich M, Schauer A: Determination of c-erbB-2 translational product p185 in serum of breast cancer patients. J Cancer Res Clin Oncol 119: 249-252, 1993
11. Carney WP, Hamer PJ, Petit D, Retos C, Greene R, Zabrecky JR, McKenzie S, Haves D, Kufe D, DeLellis R, Naber S, Wolle H: Detection and quantitation of the human neu protein. J Tumor Marker Oncol 6: 53-72, 1991
12. Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, Sakamoto G, Akiyama T, Ogowa M, Shiraishi M, Toyoshima K, Yamamoto T: In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 81: 489-494, 1990
13. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10: 1436-1443, 1992
14. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI: The extracellular domain of c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8: 2917-2923, 1993
15. Zabrecky JR, Lam T, McKenzie SJ, Carncy W: The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266: 1716-1720, 1991
16. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994
17. Boland J, Carey G, Krodel E, Kwiatkowski M: Ciba Corning ACS: 180 benchtop immunoassay analyzer. Clin Chem 36: 1598, 1990
18. Weitz S, Gorrin G, Jeschke M, Carne L, Trujillo K, Xu X, Teramoto Y: ACS Her-2, an automated immunoassay for the detection of the human Her-2 (c-erbB-2 or NEU) gene product in the serum or plasma of breast cancer patients. Clin Chem 41: 231, 1995
19. Leitzel K, Teramoto Y, Konrad K, Chincilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 129-135, 1995
20. Isola JJ, Holli K, Oksa H, Teramoto Y, Kallioniemi OP: Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 73: 652-658, 1994
21. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, Farrus B, Latre ML, Gimenez N, Hogue M, Estape J. Ballesta AM: c-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res (in press)
22. Narita T, Funahashi H, Satoh Y, Takagi H: c-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 24: 97-102, 1992
23. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P: Prognostic and predictive relevance of c-erbB-2 and ras in node-positive and negative breast cancer. Anticancer Res 14: 1441-1450, 1994
24. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 7: 1049-1056, 1992
25. Van De Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer. N Engl J Med 319: 1239-1245, 1988
26. Anderson TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL: Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to c-erbB-2 gene amplification and c-erbB-2 protein expression in tumor. Acta Oncol 34: 499-504, 1995
27. Kandl H, Seymour L, Bezwoda WR: Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 70: 739-742, 1994
28. Henderson IC, Allegra JC, Woodcock T, Wolff S. Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560-571, 1969
29. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall E, Wu K, Rosner G, Gilberg C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1132-1143, 1993
30. Ayash LJ: High-dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancer. Cancer 74: 532-535, 1994